Table 2.
Clinical parameters, histone mutation status, and treatment of cases in the control cohort.
| # | Center | Age (years) | Gender | Localization | H3 mutation | First-line treatment | Second-line treatment | OS (months) |
|---|---|---|---|---|---|---|---|---|
| 5 | Brno | 4.9 | f | Pons | IHC | Nimotuzumab/vinorelbine | 19.0 | |
| 6 | Brno | 8.2 | m | Pons | IHC | Nimotuzumab/vinorelbine | Re-RTX | 15.0 |
| 11 | Vienna | 5.9 | f | Pons | H3F3A | Temozolomide | Re-RTX, everolimus | 19.7 |
| 13 | Vienna | 8.8 | m | Pons, mesencephalon | H3F3A | Tumor vaccination | Immune checkpoint inhibitors | 10.7 |
| 14 | Vienna | 2.4 | m | Pons | HIST1H3B | Temozolomide, tumor vaccination | Re-RTX | 20.4 |
| 15 | Vienna | 8.4 | m | Pons | H3F3A | Temozolomide | 16.8 | |
| 16 | Vienna | 9.8 | f | Thalamus | H3F3A | Temozolomide | Intrathecal VP-16, PEI | 7.9 |
| 17 | Vienna | 11.1 | m | Pons, cerebellum | IHC | Nimotuzumab/vinorelbine | Re-RTX, PEI | 19.4 |
| 18 | Vienna | 4.4 | m | Pons, mesencephalon | IHC | Nimotuzumab/vinorelbine | PEI | 17.8 |
OS, overall survival; IHC, immunohistochemistry.